Cart
sales@molnova.com
Bufuralol
CAS No. 54340-62-4
Bufuralol( —— )
Catalog No. M34536 CAS No. 54340-62-4
Bufuralol (Ro 3-4787) is an orally active β-adrenergic receptor blocker with a certain degree of sympathomimetic effects and can be used to study cardiovascular diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 371 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBufuralol
-
NoteResearch use only, not for human use.
-
Brief DescriptionBufuralol (Ro 3-4787) is an orally active β-adrenergic receptor blocker with a certain degree of sympathomimetic effects and can be used to study cardiovascular diseases.
-
DescriptionBufuralol(Ro 3-4787) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdrenergic Receptor
-
RecptorAdrenergic Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number54340-62-4
-
Formula Weight261.36
-
Molecular FormulaC16H23NO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (382.61 mM; Ultrasonic (<60°C)
-
SMILESOC(C=1OC2=C(C=CC=C2CC)C1)CNC(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. T H Pringle, et al. Pharmacodynamic and pharmacokinetic studies on bufuralol in man. Br J Clin Pharmacol. 1986 Nov;22(5):527-34.?
molnova catalog
related products
-
Faxeladol
Faxeladol, a potent adrenergic absorption inhibitor and serotonin reuptake inhibitor, is a small-molecule Opioid receptor agonist that can be used to study neurological disorders.
-
Atipamezole
Antipamezole (MPV-1248) is a potent, specific α2-adrenoceptor antagonist with Ki of 1.6 nM.
-
Olodaterol
A potent, selective long-acting β2 adrenoceptor agonist with EC50 of 1.4 nM for hβ2; shows >250 fold selectivity over hβ1; exerts a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects.COPDPhase 3 Clinical
